Vir Biotechnology Reports 88% Undetectable HDV RNA at 96 Weeks with Tobevibart and Elebsiran Combination Therapy

Vir Biotechnology Inc. has announced new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta $(CHD)$. The combination therapy of tobevibart, an investigational neutralizing monoclonal antibody, and elebsiran, an investigational small interfering RNA, demonstrated increased and sustained viral suppression of HDV RNA compared to the antibody alone in participants who have reached Week 96 of treatment. The combination therapy was well tolerated and achieved undetectable HDV RNA in 88% of evaluable participants at 96 weeks. Additionally, safety and efficacy data from the Phase 1 trial of VIR-5500, Vir’s PSMA-targeted PRO-XTEN® dual-masked T-cell engager being evaluated in prostate cancer, will be presented in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in February. The company also noted it will report initial topline data from its Phase 3 CHD program in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112023074) on January 12, 2026, and is solely responsible for the information contained therein.